Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD

British Journal of Clinical Pharmacology

Volumn 50, Issue 5, 2000, Pages 449-454

  Kirchner, Gabriele I ^a   Winkler, Michael ^a   Mueller, Lueke ^a   Vidal, Christian ^a   Jacobsen, Wolfgang ^a   Franzke, Anke ^a   Wagner, Siegfried ^a   Blick, Stefan ^a   Manns, Michael P ^a   Sewing, Karl Friedrich ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cyclosporin; Drug metabolism; Electrospray MS; Metabolites; Pharmacokinetics; SDZ RAD; Therapeutic drug monitoring

Indexed keywords

40 O NOR(2 HYDROXYETHYL)RAPAMYCIN; CYCLOSPORIN; DIHYDROXY 40 O (2 HYDROXYETHYL)RAPAMYCIN; DIHYDROXYCYCLOSPORIN; DRUG METABOLITE; EVEROLIMUS; HYDROXY 40 O (2 HYDROXYETHYL)RAPAMYCIN; HYDROXYCYCLOSPORIN; PREDNISONE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG MONITORING; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MALE; MASS SPECTROMETRY; MULTICENTER STUDY; PRIORITY JOURNAL; STEADY STATE; STEREOCHEMISTRY;

ADMINISTRATION, ORAL; ADULT; CHROMATOGRAPHY, LIQUID; CLINICAL TRIALS, PHASE I; CYCLOSPORINE; CYCLOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYLATION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTICENTER STUDIES; SIROLIMUS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 0033729567     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00293.x     Document Type: Article

References (21)

1. Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription
2. Cyclosporin A and FK506: Molecular mechanisms of immunosuppression and probes and transplantation biology
3. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation
4. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo
5. SDZ RAD, a new rapamycin derivative
6. Neurological complications in the European multicentre study of FK506 and cyclosporin in primary liver transplantation
7. Cyclosporine A and hypertension
8. Renal complications and development of hypertension in the European study of FK506 and cyclosporin in primary liver transplant recipients
9. Adverse effects of FK506 overdosage after liver transplantation
10. Cyclosporine
11. Cyclosporine: Lessons learned - Future strategies
12. In vitro metabolism of FK506 in rat, rabbit, and human liver microsomes: Identification of a major metabolite and of cytochrome P-450 3A as the major enzymes responsible for its metabolism
13. Cytochrome P450 3A, enzymes are responsible for biotransformation of FK. 506 and rapamycin in man and rat
14. Sewing K-Fr Structural elucidation by electrospray mass spectrometry - An approach to the in vitro metabolism of the macrolide immunosuppressant SDZ RAD
15. LC/ESI-MS allows simultaneous and specific quantification of SDZ RAD and ciclosporin including their metabolites in human blood
16. Molecular mechanism of cyclosporine A drug interactions: Inducers and inhibitors of cytochrome P450 screening in primary cultures of human hepatocytes
17. Cyclosporin clinical pharmacokinetics
18. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients - A concentration-controlled comparison with the commercial formulation
19. Cyclosporine pharmacokinetics and variability from a microemulsion formulation - A multicenter investigation in kidney transplant patients
20. Cyclosporine metabolism in transplant patients